Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Temporary RV VVI pacing · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Standard PCI procedure + pacing post conditioning |
| 2 | NO_INTERVENTION | Standard PCI procedure |
| Name | Type | Description |
|---|---|---|
| Temporary RV VVI pacing | DEVICE | temporary pacing at the onset of revascularisation |
Inclusion Criteria: * Clinical diagnosis of acute myocardial infarction, requiring PCI within 2 to 6 hours following symptoms * Total occlusion of a coronary artery with reference vessel diameter \>or= 3mm Exclusion Criteria: * Thrombolitics * Severe bradycardia requiring cardiac pacing * Previou...
Temporary RV VVI pacing is an investigational cardiovascular therapy being studied for use in Acute Myocardial Infarction. It is intended to protect the heart from damage caused by a blocked heart vessel and from re-opening blocked vessels. The treatment is currently in Phase 2 clinical development.
Temporary RV VVI pacing is being developed by Boston Scientific Corporation, which trades under the ticker BSX. The company is conducting clinical research on this investigational therapy for Acute Myocardial Infarction.
Temporary RV VVI pacing is in Phase 2 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its use in patients with Acute Myocardial Infarction.
Temporary RV VVI pacing has one completed Phase 2 clinical trial registered as NCT00409604, titled PROTECT: Pacing to Protect Heart for Damage From Blocked Heart Vessel and From Re-opening Blocked Vessel(s). The trial enrolled 60 participants with Acute Myocardial Infarction in the Netherlands.
Temporary RV VVI pacing is a distinct investigational therapy and no alternative names have been reported. It is being studied specifically for Acute Myocardial Infarction and is not known to be identical to any other approved or investigational drug.